Study at ASH Annual Meeting finds Remestemcel-L better than Ruxolitinib for SR-aGvHD treatment. Remestemcel-L showed superior outcomes in remission rates compared to Ruxolitinib.
On December 11, 2025, Mesoblast Limited, a global leader in allogeneic cellular medicines for inflammatory diseases, disclosed that an independent comparative analysis at the 67th ASH Annual Meeting in Florida showcased the efficacy and safety contrast between remestemcel-L and ruxolitinib for treating steroid-refractory acute graft versus host disease (SR-aGvHD). The study authors affirmed that remestemcel-L exhibited better results in complete and overall remission in comparison to ruxolitinib. Mesoblast Limited is listed on Nasdaq as MESO and ASX as MSB.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments